Literature DB >> 17655935

ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology.

I Klejbor1, E K Stachowiak, D J Bharali, I Roy, I Spodnik, J Morys, E J Bergey, P N Prasad, M K Stachowiak.   

Abstract

Studies have shown the presence of expanded polyQ containing proteins in brain cells related to Huntington disease (HD) and other poly-glutamine disorders. We report the use of organically modified silica (ORMOSIL) nanoparticles as an efficient non-viral gene carrier in an effort to model brain pathology associated with those disorders induced by expanded polyQ peptides. In experiment 1, plasmids expressing Hemaglutinin-tagged polypeptides with 20 glutamine repeats (Q20) or with extended 127-glutamine repeats (Q127) were complexed with ORMOSIL nanoparticles and injected twice (2 weeks apart) into the lateral ventricle of the mouse brain. Fourteen days post-injection of Q127, immunocytochemistry revealed the presence of the characteristic nuclear and cytoplasmic Q127 aggregates in numerous striatal, septal and neocortical neuronal cells as well as ubiquitin-containing aggregates indicative of the neuronal pathology. The mice receiving Q127 showed a marked increase in the reactive GFAP (+) astrocytes in striatum, septum and brain cortex, further indicating the neurodegenerative changes, accompanied by motor impairments. In experiment 2, plasmids Q20 or Q127 were complexed with ORMOSIL and were injected into the brain lateral ventricle or directly into the striatum of adult rats. In both routes of transfection, Q127 induced the appearance of reactive GFAP (+) astrocytes and activated ED1 antigen expressing microglia. An increase in the size of the lateral ventricle was also observed in rats receiving Q127. In transgenic mouse polyQ models, extensive pathologies occur outside the nervous system and the observed brain pathologies could reflect developmental effects of the toxic polyQ proteins. Our experiments show that the nervous tissue restricted expression of poly Q-extended peptides in adult brain is sufficient to evoke neuropathologies associated with HD and other polyQ disorders. Thus, nanotechnology can be employed to model pathological and behavioral aspects of genetic brain diseases in mice as well as in other species, providing a novel research tool for in vivo testing of single or multi-gene therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17655935     DOI: 10.1016/j.jneumeth.2007.06.011

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  11 in total

Review 1.  Nonviral gene transfection nanoparticles: function and applications in the brain.

Authors:  Indrajit Roy; Michal K Stachowiak; Earl J Bergey
Journal:  Nanomedicine       Date:  2008-03-03       Impact factor: 5.307

2.  Gold nanorod--siRNA induces efficient in vivo gene silencing in the rat hippocampus.

Authors:  Adela C Bonoiu; Earl J Bergey; Hong Ding; Rui Hu; Rajiv Kumar; Ken-Tye Yong; Paras N Prasad; Supriya Mahajan; Kelly E Picchione; Arin Bhattacharjee; Tracey A Ignatowski
Journal:  Nanomedicine (Lond)       Date:  2011-06       Impact factor: 5.307

Review 3.  Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.

Authors:  Chaitanya R Joshi; Vinod Labhasetwar; Anuja Ghorpade
Journal:  J Neuroimmune Pharmacol       Date:  2017-02-03       Impact factor: 4.147

Review 4.  Available and emerging treatments for Parkinson's disease: a review.

Authors:  Patrick Hickey; Mark Stacy
Journal:  Drug Des Devel Ther       Date:  2011-05-02       Impact factor: 4.162

5.  Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer.

Authors:  Dhruba J Bharali; Murat Yalcin; Paul J Davis; Shaker A Mousa
Journal:  Nanomedicine (Lond)       Date:  2013-02-28       Impact factor: 5.307

Review 6.  Nanotechnology, nanotoxicology, and neuroscience.

Authors:  Won Hyuk Suh; Kenneth S Suslick; Galen D Stucky; Yoo-Hun Suh
Journal:  Prog Neurobiol       Date:  2008-09-24       Impact factor: 11.685

Review 7.  Intrathecal drug delivery in the era of nanomedicine.

Authors:  M J Fowler; J D Cotter; B E Knight; E M Sevick-Muraca; D I Sandberg; R W Sirianni
Journal:  Adv Drug Deliv Rev       Date:  2020-03-03       Impact factor: 15.470

8.  Chronic constriction injury-induced nociception is relieved by nanomedicine-mediated decrease of rat hippocampal tumor necrosis factor.

Authors:  Elizabeth Gerard; Robert N Spengler; Adela C Bonoiu; Supriya D Mahajan; Bruce A Davidson; Hong Ding; Rajiv Kumar; Paras N Prasad; Paul R Knight; Tracey A Ignatowski
Journal:  Pain       Date:  2015-07       Impact factor: 7.926

9.  Active targeting of HER2-positive breast cancer cells by Herceptin-functionalized organically modified silica nanoparticles.

Authors:  Vahid Shirshahi; Fereshteh Shamsipour; Amir Hassan Zarnani; Javad Verdi; Reza Saber
Journal:  Cancer Nanotechnol       Date:  2013-03-27

10.  CD151 mediates netrin-1-induced angiogenesis through the Src-FAK-Paxillin pathway.

Authors:  Xiaosheng Yang; Shiting Li; Jun Zhong; Wenchuan Zhang; Xuming Hua; Bin Li; Hui Sun
Journal:  J Cell Mol Med       Date:  2016-08-25       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.